Operative Management of Renovascular Hypertension

Renovascular hypertension: problems in evaluation and management.

A 63-year-old white man was referred for evaluation of hypertension. He had an elevated BP for approximately 10 years. Medications had been administered for approximately 7 years, but during the past 2 years, his BP had become more difficult to control, requiring increasing doses of metoprolol and lisinopril. Home monitoring of BP generally yielded values ranging from 150 to 180 mm Hg systolic ...

Renovascular Hypertension

The effect of hypertension and of therapy by converting enzyme inhibitor (S 9490-3, perindopril) on the function and structure of large arteries has been studied in two-kidney, one-clip Gddblatt hypertensive rats. After one month without treatment, clipped hypertensive rats (n = 24) and sham-operated rats (n = 24) were randomly allocated to treatment by S 9490,1 mg/kg once a day (n = 24) or to ...

Renovascular hypertension.

If only 1 per cent of the 23 million hypertensive patients in the United States had renovascular hypertension, many patients would be denied the chance for cure. Strong clinical suspicion plus arteriography are the mainstays of diagnosis. Positive renal vein renin studies provide the best preoperative evidence for cure by operation, but many patients with negative studies benefit from operation...

ACR Appropriateness Criteria ® 2 Renovascular Hypertension RENOVASCULAR HYPERTENSION Expert

Systemic and renovascular hypertension.

To ascertain the contribution of systemic hypertension in the progression of renal failure, we have studied the effects of pharmacological treatment of hypertension in rats with the remnant kidney model of renal insufficiency, streptozotocin diabetes, or nephrotoxic serum nephritis. Treatment with the angiotensin converting enzyme (ACE) inhibitor enalapril lowered systemic blood pressure in the...